Alzheimer's Blood Test: What Early Detection Can Do

For decades, confirming Alzheimer's disease meant a spinal tap or an expensive brain scan.

In May 2025, that changed. The FDA cleared the first blood test that can help identify one of the disease's key markers, and it's already reshaping how doctors evaluate memory problems.

What the Test Actually Measures

The test is called the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, made by Fujirebio Diagnostics. The name is a mouthful, but the idea behind it is fairly simple. It measures the ratio between two proteins in the blood, a form of tau protein and a form of amyloid beta, both of which are tied to the buildup of amyloid plaques in the brain.

Amyloid plaques are clumps of protein that build up between brain cells and are considered one of the earliest physical signs of Alzheimer's disease. Until recently, the only reliable ways to detect them were a PET brain scan or a cerebrospinal fluid test drawn from a spinal tap. Both work, but both are expensive, and a spinal tap isn't something most patients look forward to.

A blood draw is neither of those things. That's the real appeal here, and it's a fair one.

Who This Test Is Actually For

This is the part that gets lost in a lot of the coverage, so it's worth being precise. The FDA cleared this test for adults aged 55 and older who are already showing signs of cognitive decline and are being evaluated by a specialist. It is not approved for screening healthy people who have no symptoms, and it's not meant to be used on its own to diagnose Alzheimer's.

That distinction matters more than it sounds. If a 70-year-old with no memory concerns wants to order this test just because a parent had Alzheimer's, that's a different use case entirely from what the FDA reviewed, and most doctors won't recommend it that way. The test was studied and cleared for people already experiencing cognitive symptoms, evaluated by a clinician who's looking at the full picture, not as a standalone worry-reducer for someone who feels fine.

It's also worth knowing that "FDA-cleared" and "FDA-approved" mean slightly different things in regulatory terms, and you'll see both used loosely in coverage of this test. The Lumipulse test went through the FDA's 510(k) clearance pathway, which is the standard route for many diagnostic tools. In clinical practice, this distinction rarely changes how a doctor uses the result, but it's the kind of detail that separates careful reporting from marketing copy.

How Accurate Is It, Really

In the study submitted to the FDA, the test correctly identified amyloid-positive patients about 92% of the time compared against amyloid PET scans, and correctly identified amyloid-negative patients around 97% of the time. Those numbers are strong, and they're a big part of why the FDA moved forward with clearance.

But "strong" isn't "perfect," and that gap matters here more than in most tests. A false negative could mean someone with early Alzheimer's is told the marker wasn't found, delaying further evaluation. A false positive could cause real distress before more thorough testing sorts it out. Neither outcome is common, but neither is impossible, which is exactly why this test is meant to be one piece of an evaluation, not the whole picture.

Why Early Detection Actually Matters

Here's the honest case for why this shift is meaningful, beyond convenience. Alzheimer's treatments that target amyloid, like the newer anti-amyloid drugs, tend to work best when started early in the disease process, before too much damage has accumulated. Confirming amyloid pathology sooner, and with less friction than a spinal tap, means more people might actually get evaluated who would otherwise put it off.

That's not a small thing. A lot of families wait months or years past the first noticeable memory changes before pursuing a real workup, partly out of fear and partly because the process has historically been such a hassle. A blood draw lowers that barrier meaningfully.

What a Positive Result Doesn't Mean

A positive result means amyloid plaques are likely present. It does not, by itself, mean someone has Alzheimer's disease, and it doesn't predict how quickly symptoms will progress.

Diagnosis still requires the fuller picture: a clinical history, cognitive testing, a physical exam, and often imaging, put together by a doctor who knows the patient. If you or a loved one gets this test done, treat the result as one input for a geriatrician or neurologist to interpret, not a verdict to sit with alone. A specialist can walk through what the number actually means for that specific person's symptoms and history, which a lab report on its own simply can't do.